This bill would create a new law by adding a section to chapter 70.14 RCW that bars a state agency, county, city, or town from purchasing an "opioid overdose reversal medication" from any entity (including that entity’s affiliates or subsidiaries) that, at the time of purchase, has been a party to a settlement with any state government over claims of having participated in causing or fueling the opioid epidemic. The bill defines the medication by reference to RCW 69.41.095 and includes an express exception allowing an entity that agreed to provide such medication as part of a state settlement entered into before September 1, 2024, to continue providing those medications until its existing settlement obligations are fulfilled. The bill also requires the Department of Health to maintain a public website list of entities from which purchases are prohibited as described above. The bill text includes legislative findings about certain corporations having been parties to settlements and the state’s interest in purchasing from distributors that were not parties to those settlements. The extracted material does not include the text of RCW 69.41.095, so the precise statutory definition of "opioid overdose reversal medication" is not provided here. The bill does not specify how it is determined that an entity "has been a party to a settlement," does not define "affiliate" or "subsidiary," and contains no enforcement provisions, penalties, procurement procedures, effective date, or timelines and criteria for how or when the Department of Health must publish or update the prohibited-entity list. The bill sponsor is Representative Reeves; it was read for the first time on 01/20/25 and referred to the Committee on Health Care & Wellness.

If enacted, state agencies and local governments would no longer be able to buy opioid overdose reversal medicines from companies that have been parties to state opioid settlement agreements, narrowing the pool of vendors they can use and likely forcing procurement officers to find alternative suppliers or renegotiate contracts. Companies that already agreed before September 1, 2024 to provide these medicines as part of a settlement could keep supplying until those settlement obligations end, but other settled companies would lose access to public purchasers, which could reduce their sales to government entities and shift costs or sourcing burdens onto the public sector if replacement suppliers are more expensive or less available. The Department of Health would have to publish and maintain a public list of the prohibited entities, creating a new administrative task for the agency and a new step for procurement staff to check, but the bill text does not say how quickly the list must be updated, how a company is officially determined to have “been a party to a settlement,” what exactly counts as an overdose reversal medication, or how the prohibition would be enforced; those gaps leave uncertainty about timing, compliance procedures, and the risk of supply disruptions.